About the Program
The Advances in Chronic Hepatitis C: Management and Treatment program is a comprehensive, expert review of the 50th Annual Meeting of the European Association for the Study of the Liver (EASL 2015). This program consists of five components: (1) CME Internet Symposium: EASL 2015 Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) CME Internet Symposium: European Perspective on EASL 2015: a 1-hour Internet symposium featuring Europe-based expert faculty reviewing and discussing key presentations with a focus on management and treatment in the EU; (3) CME Internet Symposium: Brazilian Perspective on EASL 2015: a 1-hour Internet symposium featuring Brazil-based expert faculty reviewing and discussing key presentations with a focus on management and treatment in Brazil; (4) Rapid-Fire Review of EASL 2015: a podcast that provides a brief, audio summary of the essential data presented at the conference; and (5) From Conference to Clinic: Reviewing and Applying Data from EASL 2015: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care. The CME Internet Symposium: Brazilian Perspective on EASL 2015 will provide a Brazilian focused review and discussion of the key studies on chronic hepatitis C presented at EASL 2015. The expected result is that Brazil-based participants will not only gain an increased understanding of key data presented at EASL 2015, they will also be better prepared to address their HCV patients’ health needs and provide optimal care, which should improve treatment and adherence, increase individualized care, reduce adverse effects and drug-drug interactions, and improve quality of life for people with chronic hepatitis C throughout Brazil.
All online components of the program will be accessible at www.viraled.com.
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at EASL 2015 and it is not sanctioned by the organizers of EASL 2015.
Back to Top
This activity is intended for physicians, physician assistants, advanced practice nurses, and other health care professionals in Brazil involved in the
treatment and management of patients with HCV infection.
After completing this activity, the participant should be better able to:
Use in a clinical setting in Brazil, important findings from key studies on CHC diagnosis and treatment presented at EASL 2015
Employ the current treatment paradigms for CHC applicable in Brazil, including the studies and data presented at EASL 2015 to improve patient care
Discuss with patients and colleagues how the studies and data on newer therapies for CHC presented at EASL 2015 affect appropriate planning of therapy for patients with CHC in Brazil
Release Date: May 4, 2015
Expiration Date: May 4, 2016
Estimated time to complete the EASL 2015 Brazil Internet Symposium: 1 hour, 15 minutes
Back to Top
Mário G. Pessoa, MD, PhD
Division of Gastroenterology and Hepatology
University of São Paulo School of Medicine
São Paulo, Brazil
Mauro Schechter, MD, PhD
Professor of Infectious Diseases
Department of Preventive Medicine
Federal University of Rio de Janeiro, Brazil
Rio de Janeiro, Brazil
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors,
planners, managers and other individuals who are in a position to
control the content of this activity to disclose any real or apparent
conflict of interest (COI) they may have as related to the content of
this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to provideing its learners
with high quality CME activities and related materials that promote
improvements or quality in healthcare and not a specific proprietary
business interest of a commerical interest.
Mario Pessoa, MD
- Consulting Fees: Abbvie, Roche, Janssen, BMS, Gilead, Merck
- Fees for Non-CME/CE Services: Abbvie, Roche, Janssen, BMS, Gilead, Merck
- Contracted Research: Abbvie
Mauro Schechter, MD
The planners and managers reported the following financial
relationships or relationships to products or devices they or their
spouse/life partner have with commercial interests related to the
content of these CME activities:
- Consulting Fees: Achillion, BMS, Gilead, Abbvie, Merck, Janssen, Roche
The following PIM staff serve as clinical content reviewers and/or
participate in planning CME/CE activities in a manner that may affect
content:, Judi Smelker-Mitchek, RN, BSN; Trace Hutchison,
PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Shultz, RN, MSN, CCMEP
and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their
spouse/life partner do not have any financial relationships or
relationships to products or devices with any commercial interests
related to the content of this CME/CE activity of any amount during the past 12 months.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period, May 4, 2015 through May 4, 2016, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If
you wish to received acknowledgment of completing this activity, please
complete the post-test and evaluation on www.cmeuniveristy.com. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 10851.
Upon registering and successfully completing the post-test with a score
of 70% or better and the activity evaluation, your certificate will be
made available immediately. Processing credit requests online will
reduce the amount of paper used by nearly 100,000 sheets per year.
Disclosure of Unlabeled Use
educational activity may contain discussion of published and/or investigational
uses of agents that are not indicated by the FDA. The planners of this activity
do not recommend the use of any agent outside of the labeled indications.
opinions expressed in the educational activity are those of the faculty and do
not necessarily represent the views of the planners. Please refer to the
official prescribing information for each product for discussion of approved
indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to
serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without
evaluation of their patient's conditions and possible contraindications
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs.
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at EASL 2015 and it is not sanctioned by EASL 2015.